Discontinued — last reported Q2 '20
Royalty Pharma Lease Liability Payments - Due Year Two decreased by 1.5% to $3.72M in Q1 2026 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Provides insight into the company's fixed cost commitments and long-term operational leverage.
The projected cash payments for operating and finance leases scheduled for the second year following the balance sheet d...
Standard disclosure for lease maturity profiles.
lease_liability_payments_due_year_2| Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|
| Value | $3.78M | $3.78M | $3.72M |
| QoQ Change | — | +0.0% | -1.5% |